ValueAct Gets Boost from Valeant Deal

The activist investment firm is the third largest shareholder in the pharmaceutical company, whose shares surged on news it was acquiring Bausch & Lomb.

Stephen Taub May 29, 2013

Valeant Pharmaceuticals International’s acquisition of Bausch & Lomb for $8.7 billion in cash is a big boon for a handful of savvy hedge fund managers, especially Jeffrey Ubben. Ubben runs the ValueAct Holdings hedge fund out of ValueAct Capital, his San Francisco–based investment firm. ValueAct

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.14.11 build:2026-01-27 Login